
Obesity week 2026 Preview – Clinical and AI / ML



LucidQuest Intelligence
Accelerate your success

Obesity week 2026 Preview – Table of Contents

- New Trends in Obesity Treatment Strategy At Obesity week'26 3-5
- Key Sessions To Watch 6
- Industry-sponsored Sessions & Focus Areas At Obesity week'26 7-14
  - Competitive Landscape At a Glance at Obesity week'26 8-9
  - Key Industry-sponsored Sessions At Obesity week'26 10-13
  - New Entrants 14
- AI/ML Trends & Strategic Watchpoints At Obesity week'26 15-18
  - AI / Digital Health Angle At Obesity week 2026 16-18
- What We're Watching For Post-congress 19
- Get In Touch With LucidQuest 20

Obesity week 2026 – New Trends in Obesity Treatment Strategy (1/3)

- **Obesity treatment success will increasingly be discussed in terms of body composition, not weight loss alone**
  - ObesityWeek 2026 will bring body composition, visceral fat and lean-mass preservation into the treatment discussion. Sessions will examine the clinical relevance of body composition and the INHBE–Activin E pathway, while the programme also includes research on exercise and protein strategies to preserve lean mass during GLP-1 agonist therapy. The discussion will extend beyond the amount of weight lost to the nature of that loss and its potential implications for health
- **Amylin biology will feature alongside established incretin-based approaches**
  - The programme includes a Novo Nordisk-supported symposium on the immunobiology of obesity and the role of amylin, as well as abstracts exploring amylin-receptor drug discovery and GLP-1R/amylin receptor dual agonism. Additional research covers multi-receptor approaches involving GIP, GLP-1, glucagon and other metabolic pathways. The range of mechanisms will suggest that obesity drug development is continuing to explore complementary pathways beyond single-receptor strategies

Obesity week 2026 – New Trends in Obesity Treatment Strategy (2/3)

- **Treatment durability and discontinuation will remain central to real-world obesity management**
  - ObesityWeek 2026 will address reasons for GLP-1 receptor agonist discontinuation, weight regain after treatment cessation and predictors of sustained weight loss. A conference will include a large language model analysis of reasons for GLP-1 receptor agonist discontinuation and a prognostic model for weight regain following discontinuation. The programme will place treatment persistence and the management of interruptions alongside efficacy
- **Obesity pharmacotherapy will be considered across a wider range of patient groups and care settings**
  - The dedicated sessions on paediatric obesity pharmacotherapy, acquired hypothalamic obesity, obesity in older adults, and the management of obesity alongside MASLD. Novo Nordisk will support a two-day paediatric obesity pre-conference course, while Rhythm Pharmaceuticals has sessions on acquired hypothalamic obesity. The focus will be on specific populations and obesity-related conditions highlights the need for treatment approaches that account for underlying disease characteristics and patient needs

Obesity week 2026 – New Trends in Obesity Treatment Strategy (3/3)

- **The relationship between pharmacotherapy, nutrition and bariatric surgery will receive greater attention**
  - The programme will examine how obesity medications fit alongside nutritional assessment, behavioural interventions and metabolic bariatric surgery. Sessions include Bariatric Surgery: What's New, What's True and What's Next?, which will discuss evolving procedures and the complementary role of surgery and highly effective obesity medications

- **Access, coverage and patient experience will remain important barriers to treatment delivery**
  - Dedicated programme content will address medication access, coverage, equity, adherence and patient engagement. The programme will also include research on coverage gaps for GLP-1-based receptor agonists and real-world treatment patterns. These discussions bring affordability and continuity of care into the broader treatment conversation

Key Sessions To Watch

Date	Session Title (short)	Type	Author / Institution	Why Watch
14 Nov 2026	Rethinking Success in the Treatment of Overweight and Obesity Through Body Composition: What Are We Made Of?	Corporate-Supported Symposium	Angela Fitch; Christopher Wright; Mehmet Furkan Burak; Erik Ingelsson	Body composition, fat distribution, lean mass and the INHBE–Activin E pathway
14 Nov 2026	The Missing Piece in the Obesity Puzzle: Exploring the Immunobiology of Obesity and the Role of Amylin	Corporate-Supported Symposium	Daniel H. Bessesen; Timothy Garvey; Emily Goldberg; Priya Jaisinghani	Amylin biology and its role in obesity treatment
15 Nov 2026	Treatment Access, Coverage, and Real-World Outcomes	Oral Session	John D. Clark; Alison Sexton Ward; M. Rami Bailony; Cristina JY.	Real-world GLP-1 use, reimbursement of obesity counselling and treatment costs
15 Nov 2026	Bariatric Surgery: What's New, What's True and What's Next?	Symposium	John Morton; Enrique F. Elli; Vance L. Albaugh; Sriram Machineni	New surgical approaches and the role of bariatric surgery alongside obesity medications
15 Nov 2026	Shifting Coverage: The Evolving Insurance Landscape for Obesity Medications	Symposium	Kristina H. Lewis; Christine Gallagher; Alison Sexton Ward; Angela Fitch	Cost-effectiveness and access through Medicare, Medicaid and commercial insurance
16 Nov 2026	Beyond Counting Steps: Wearables as Engines of Metabolic Change	Key Lecture	Matthew P. Buman; Sarah-Jeanne Salvy	Wearable technologies and their role in metabolic health
16 Nov 2026	Precision Medicine, Artificial Intelligence, and Predictive Modeling	Oral Session	Juan M. Garcia Cordova; Kathleen M. Robinson; Absalon D. Gutierrez	Machine-learning approaches to treatment response, visceral adipose tissue and semaglutide mechanisms

Industry-Sponsored Sessions & Focus Areas – Obesity week 2026



Obesity week 2026– Competitive Landscape at a Glance (1/2)

Name	Sessions	Companies / Assets	Why It Matters
Incretin-based obesity therapies	Multiple	Novo Nordisk / semaglutide, cagrilintide, CagriSema; Eli Lilly / tirzepatide, Zepbound	Programme coverage spans treatment response, real-world use, discontinuation and treatment outcomes, keeping established incretin therapies central to the discussion
Amylin and multi-receptor approaches	Multiple	Novo Nordisk / amylin-focused programme; investigational amylin receptor and GLP-1R/amylin approaches; NMUR2–GIPR and other multi-receptor candidates	Amylin will have dedicated symposium coverage, while emerging research explores additional combinations and metabolic targets
Body composition and lean-mass preservation	Multiple	Wave Life Sciences / INHBE–Activin E pathway; research on muscle preservation and body composition	The programme will give greater attention to fat distribution, lean mass and the quality of weight loss as treatment considerations
Obesity and MASLD	Multiple	Boehringer Ingelheim	Obesity and metabolic dysfunction-associated steatotic liver disease will be addressed together, linking weight management with metabolic complications

Obesity week 2026– Competitive Landscape at a Glance (2/2)

Name	Sessions	Companies / Assets	Why It Matters
Treatment access and coverage	Multiple	Research on GLP-1 treatment access, commercial insurance reimbursement, Medicare and Medicaid coverage, and cost-effectiveness	Access and affordability will be addressed through both scientific research and a dedicated insurance coverage symposium
Digital health and AI-enabled obesity care	Multiple	Digital obesity programmes, telehealth, CGM-integrated interventions, AI-enabled tools and wearables	Research covers remote care, patient engagement, predictive modelling and technology-supported behaviour change
Acquired hypothalamic obesity	Multiple	Rhythm Pharmaceuticals	Dedicated sessions to address diagnostic criteria and recognition of acquired hypothalamic obesity in children and adults
Emerging metabolic targets	Multiple	INHBE, Activin E, ALK7, GPR75, MC4R, NMUR2–GIPR and amylin-related approaches	A broad range of early research explores targets beyond established incretin pathways, although several approaches remain preclinical

Key Industry-Sponsored Sessions at Obesity week 2026 (1/4)

- **Wave Life Sciences:**
  - Focus Areas: Body Composition, Lean-Mass Preservation and the INHBE–Activin E Pathway
  - Wave Life Sciences' programme will examine whether weight loss alone is sufficient to define successful obesity treatment. The symposium includes the clinical relevance of body composition, body fat distribution and lean mass, followed by a discussion of the INHBE–Activin E pathway as a potential therapeutic target. The session will also consider how new obesity therapies may affect body composition
- **Novo Nordisk:**
  - Focus Areas: Paediatric Obesity Care and Amylin Biology
  - Novo Nordisk supports a two-day pre-conference course on comprehensive paediatric obesity care, covering medical, nutritional, behavioural and pharmacological approaches. Discussion is expected to connect the expanding treatment options with the practical requirements of paediatric care, while exploring amylin's role in future obesity treatment strategies

Key Industry-Sponsored Sessions at Obesity week 2026 (2/4)

- **Regeneron:**
  - Focus Areas: Quality of Weight Loss and Whole-Person Obesity Care
  - Regeneron's programme will focus on assessing the quality of weight loss and advancing a whole-person approach to obesity care. The session will align with the broader programme emphasis on body composition, metabolic health and treatment outcomes beyond changes in body weight
- **Amgen:**
  - Focus Areas: Treatment Burden, Discontinuation and Outcomes
  - Amgen's symposium will examine the obesity treatment journey, including treatment burden, discontinuation and outcomes. This will complement the scientific programme's focus on GLP-1 receptor agonist discontinuation, treatment interruptions and weight regain. Discussion is expected to centre on the factors that influence treatment continuity and the outcomes associated with discontinuation

Key Industry-Sponsored Sessions at Obesity week 2026 (3/4)

- **Boehringer Ingelheim:**
  - Focus Areas: Obesity, MASLD and Glucagon Biology
  - Boehringer Ingelheim's programme includes a symposium on bridging obesity and MASLD through metabolic dysfunction and a separate session on glucagon's role in metabolic regulation. Discussion is expected to connect metabolic mechanisms with the clinical overlap between obesity and liver disease
- **Eli Lilly:**
  - Focus Areas: Foundayo, Zepbound and Multidisciplinary Obesity Care
  - Eli Lilly's programme includes a corporate-supported session on Weight Management Foundayo, a session on Discover Zepbound (Tirzepatide) Injection, and a multidisciplinary expert roundtable on obesity care. The programme will also include a session on weight bias and stigma in paediatric obesity care. Discussion is expected to cover product-focused obesity management alongside multidisciplinary care and patient-centred considerations

Key Industry-Sponsored Sessions at Obesity week 2026 (4/4)

- **Rhythm Pharmaceuticals:**
  - Focus Areas: Acquired Hypothalamic Obesity and Diagnostic Recognition
  - Rhythm Pharmaceuticals has two sessions dedicated to acquired hypothalamic obesity: an international expert consensus on diagnostic criteria in children and adults, and a session titled The Obesity Diagnosis You May Be Missing: Acquired Hypothalamic Obesity. Discussion is expected to focus on recognising acquired hypothalamic obesity and improving diagnostic approaches across age groups
- **Azurity Pharmaceuticals:**
  - Focus Areas: Translating Obesity Science into Clinical Practice
  - Azurity's programme will examine the evolution of obesity management and how a maturing evidence base can be incorporated into clinical practice. Talk is expected to focus on translating developments in obesity science into practical treatment approaches

New Entrants

Asset / Company	2026 Presence
Retatrutide / Eli Lilly	Preclinical research comparing retatrutide with other investigational obesity approaches
Amylin receptor drug discovery	Research combining high-throughput cryo-EM and AI foundation models to support amylin receptor drug discovery
GLP-1R/amylin receptor dual agonist	Preclinical research on a biased dual agonist and a monthly formulation evaluated in obese rats
NMUR2–GIPR dual agonist	Preclinical research on a long-acting dual agonist targeting NMUR2 and GIPR
GPR75 antagonist	Preclinical research on a peripherally restricted antagonist as a potential oral obesity treatment
MC4R-directed approaches / HUC1-622 and DAT-9232	Preclinical research covering an oral MC4R agonist and a dual MC4R/MC3R agonist discovery programme
ALK7-targeting siRNA	Preclinical research exploring ALK7-targeting siRNA for obesity.
ASC37	Preclinical findings on half-life and weight loss in non-human primates and diet-induced obese mice

AI/ML Trends & Strategic Watchpoints at Obesity week 2026



AI / Digital Health Angle at Obesity week 2026 (1/3)

- **AI/ML activity at ObesityWeek 2026 will span obesity drug discovery, treatment-response prediction, body-composition assessment and digital weight management. The programme will explore how AI can support both the development of new therapeutic approaches and more personalised obesity care**
- **AI will extend obesity drug discovery beyond established therapeutic targets**
  - ObesityWeek 2026 will feature AI-supported approaches to amylin receptor drug discovery, including the integration of high-throughput cryo-EM and AI foundation models. Research will also explore AI-guided design of adipose-targeted delivery approaches. The focus will be on how computational tools can support target characterisation and the development of new therapeutic strategies
- **Machine learning will increasingly support treatment-response prediction and patient stratification**
  - The programme will include machine-learning approaches to predict response to semaglutide using clinical and genetic variables, alongside research exploring weight-regain prediction following treatment discontinuation. Models for estimating visceral adipose tissue and assessing metabolic risk will also feature. These applications position AI/ML as potential tools for identifying patient subgroups and supporting more personalised obesity management.

AI / Digital Health Angle at Obesity week 2026 (2/3)

- **AI-enabled assessment will connect body composition with metabolic risk**
  - Deep-learning approaches will be explored for MRI-based body-composition analysis, while machine-learning models will assess visceral adipose tissue and related metabolic measures. The growing use of computational methods in body-composition research will bring greater attention to fat distribution, lean mass and the quality of weight loss, beyond changes in body weight alone
- **Digital health will focus on engagement and behavioural support alongside obesity treatment**
  - Conference will feature AI-enabled digital weight-management programmes, virtual care and technology-supported interventions. Research will examine AI-powered meal feedback and patient engagement in digital programmes involving tirzepatide. Wearables and CGM-integrated approaches will also feature in the broader digital-health landscape
- **Key sessions include:**
  - Amylin receptor drug discovery using high-throughput cryo-EM and AI foundation models
  - Machine-learning prediction of semaglutide treatment response
  - AI-enabled digital weight-management and healthy-habit interventions
  - Beyond Counting Steps: Wearables as Engines of Metabolic Change
  - Research on machine-learning approaches to predict weight regain and metabolic risk

AI / Digital Health Angle at Obesity week 2026 (3/3)

- **Sessions suggest AI and digital tools are increasingly being used to improve:**
  - Drug discovery: AI foundation models and computational approaches to support amylin receptor research and therapeutic design
  - Treatment-response prediction: Machine-learning models combining clinical and genetic variables to estimate response to obesity treatments
  - Body-composition assessment: Deep-learning analysis of MRI data and machine-learning estimation of visceral adipose tissue
  - Risk prediction: Models exploring weight-regain risk and metabolic risk stratification
  - Patient engagement: AI-enabled feedback and digital interventions to support healthy habits and engagement during weight-management treatment
  - Behavioural monitoring: Wearables and connected technologies to support activity monitoring and metabolic-health assessment

What We're Watching for Post-Obesity week 2026

- Whether body composition, fat distribution and lean-mass preservation become more established measures of obesity-treatment success, beyond weight loss alone
- Whether amylin-based and multi-receptor approaches demonstrate a meaningful role alongside established incretin therapies
- Whether emerging evidence on treatment response helps identify which patients are most likely to benefit from specific obesity medications
- Whether weight regain following treatment discontinuation leads to greater emphasis on long-term treatment continuity and maintenance strategies
- Whether evolving insurance coverage and reimbursement translate into improved access to obesity medications across different patient populations
- Whether bariatric surgery and pharmacological treatment become more integrated within multidisciplinary obesity-care pathways
- Whether emerging targets such as INHBE–Activin E, ALK7, GPR75 and MC4R progress beyond early-stage research and attract further development interest
- Whether AI-enabled prediction, digital weight-management programmes and wearable technologies demonstrate practical value in personalising care and supporting sustained behaviour change

Strategic Insights and Strategy Development is our focus

